Towards the molecular imaging of prostate cancer biomarkers using protein-based MRI contrast agents

Current Protein and Peptide Science

Volumn 17, Issue 6, 2016, Pages 519-533

  Pu, Fan ^a   Xue, Shenghui ^a   Qiao, Jingjuan ^a   Patel, Anvi ^a   Yang, Jenny J ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Biomarkers; GRPR; Molecular imaging; Protein based MRI contrast agents; PSMA

Indexed keywords

BIOLOGICAL MARKER; BOMBESIN RECEPTOR; CAPROMAB PENDETIDE IN 111; CARBON 11; FLUORODEOXYGLUCOSE F 18; GASTRIN RELEASING PEPTIDE RECEPTOR; NEUROMEDIN B; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PROSTATE SPECIFIC MEMBRANE ANTIGEN; QUANTUM DOT; CONTRAST MEDIUM; LIGAND; MOLECULAR PROBE; MONOCLONAL ANTIBODY; PROTEIN; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; HUMAN; IMMUNOREACTIVITY; MOLECULAR IMAGING; NEAR INFRARED SPECTROSCOPY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE PLASMON RESONANCE; TRANSRECTAL ULTRASONOGRAPHY; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; MALE; METABOLISM; MOLECULAR PROBE; PROCEDURES; PROSTATE TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; LIGANDS; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR IMAGING; MOLECULAR PROBES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEINS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN;

EID: 84981521245     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1389203717666160101123725     Document Type: Article

References (166)

1. Routh, J.C.; Leibovich, B.C. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin. Proc., 2005, 80(7), 899-907.
2. Simmons, M.N.; Berglund, R.K.; Jones, J.S. A practical guide to prostate cancer diagnosis and management. Cleve. Clin. J. Med., 2011, 78(5), 321-331.
3. Menez, R.; Michel, S.; Muller, B.H.; Bossus, M.; Ducancel, F.; Jolivet-Reynaud, C.; Stura, E.A. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody. J. Mol. Biol., 2008, 376(4), 1021-1033.
4. Balk, S.P.; Ko, Y.J.; Bubley, G.J. Biology of prostate-specific antigen. J. Clin. Oncol., 2003, 21(2), 383-391.
5. Selley, S.; Donovan, J.; Faulkner, A.; Coast, J.; Gillatt, D. Diagnosis, management and screening of early localised prostate cancer. Health Technol. Assess, 1997, 1(2): 1-96.
6. Seaman, E.; Whang, M.; Olsson, C.A.; Katz, A.; Cooner, W.H.; Benson, M.C. PSA density (PSAD). Role in patient evaluation and management. Urol. Clin. North Am., 1993, 20(4), 653-663.
7. Bretton, P.R.; Evans, W.P.; Borden, J.D.; Castellanos, R.D. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer, 1994, 74(11), 2991-2995.
8. Leventhal, E.K.; Rozanski, T.A.; Morey, A.F.; Rholl, V. The effects of exercise and activity on serum prostate specific antigen levels. J. Urol., 1993, 150(3), 893-894.
9. Kane, R.A.; Littrup, P.J.; Babaian, R.; Drago, J.R.; Lee, F.; Chesley, A.; Murphy, G.P.; Mettlin, C. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer, 1992, 69(5), 1201-1207.
10. Lee, F.; Littrup, P.J.; Loft-Christensen, L.; Kelly, B.S.; Jr., McHugh, T.A.; Siders, D.B.; Mitchell, A.E.; Newby, J.E. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer. Cancer, 1992, 70(1 Suppl), 211-220.
11. Catalona, W.J.; Smith, D.S.; Ratliff, T.L.; Basler, J.W. Detection of organ-confined prostate cancer is increased through prostatespecific antigen-based screening. JAMA, 1993, 270(8), 948-954.
12. Catalona, W.J.; Partin, A.W.; Slawin, K.M.; Brawer, M.K.; Flanigan, R.C.; Patel, A.; Richie, J.P.; deKernion, J.B.; Walsh, P.C.; Scardino, P.T.; Lange, P.H.; Subong, E.N.; Parson, R.E.; Gasior, G.H.; Loveland, K.G.; Southwick, P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 1998, 279(19), 1542-1547.
13. Catalona, W.J.; Richie, J.P.; Ahmann, F.R.; Hudson, M.A.; Scardino, P.T.; Flanigan, R.C.; deKernion, J.B.; Ratliff, T.L.; Kavoussi, L.R.; Dalkin, B.L.; et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol., 1994, 151(5), 1283-1290.
14. Babaian, R.J.; Mettlin, C.; Kane, R.; Murphy, G.P.; Lee, F.; Drago, J.R.; Chesley, A. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer, 1992, 69(5), 1195-1200.
15. Babaian, R.J.; Camps, J.L. The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer, 1991, 68(9), 2060-2063.
16. Cooner, W.H.; Mosley, B.R.; Rutherford, C.L.; Jr., Beard, J.H.; Pond, H.S.; Terry, W.J.; Igel, T.C.; Kidd, D.D. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol., 1990, 143(6), 1146-1152; discussion 1152-1154.
17. Drago, J.R.; York, J.P. Prostate-specific antigen, digital rectal examination, and transrectal ultrasound in predicting the probability of cancer. J. Surg. Oncol., 1992, 49(3), 172-175.
18. Nachman, R.L. The thrombotic process in atherogenesis. Summary of workshop a: endothelium. Adv. Exp. Med. Biol., 1978, 104, 247-256.
19. Cooner, W.H.; Mosley, B.R.; Rutherford, C.L.; Jr., Beard, J.H.; Pond, H.S.; Terry, W.J.; Igel, T.C.; Kidd, D.D. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990. J. Urol., 2002, 167(2 Pt 2): 966-973; discussion 973-975.
20. Mettlin, C.; Lee, F.; Drago, J.; Murphy, G.P. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer, 1991, 67(12), 2949-2958.
21. Baran, G.W.; Golin, A.L.; Bergsma, C.J.; Stone, T.E.; Wilson, P.R.; Reichardt, B.A.; Lobert, P.F.; Locke, C.S. Biologic aggressiveness of palpable and nonpalpable prostate cancer: assessment with endosonography. Radiology, 1991, 178(1), 201-206.
22. Brawer, M.K.; Ploch, N.R.; Bigler, S.A. Prostate cancer tumor location as predicted by digital rectal examination transferred to ultrasound and ultrasound-guided prostate needle biopsy. J. Cell Biochem. Suppl., 1992, 16H, 74-77.
23. Mettlin, C. Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project. Clin. Invest. Med., 1993, 16(6), 440-447.
24. Chodak, G.W.; Schoenberg, H.W. Early detection of prostate cancer by routine screening. JAMA, 1984, 252(23), 3261-3264.
25. Chodak, G.W.; Keller, P.; Schoenberg, H.W. Assessment of screening for prostate cancer using the digital rectal examination. J. Urol., 1989, 141(5), 1136-1138.
26. Varenhorst, E.; Carlsson, P.; Capik, E.; Lofman, O.; Pedersen, K.V. Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol., 1992, 31(8), 815-821.
27. Pedersen, K.V.; Carlsson, P.; Varenhorst, E.; Lofman, O.; Berglund, K. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ., 1990, 300(6731), 1041-1044.
28. Ghai, S.; Toi, A. Role of transrectal ultrasonography in prostate cancer. Radiol. Clin. North Am., 2012, 50(6), 1061-1073.
29. Borley, N.; Feneley, M.R. Prostate cancer: diagnosis and staging. Asian J. Androl., 2009, 11(1), 74-80.
30. Washington, S.L.; Bonham, M.; Whitson, J.M.; Cowan, J.E.; Carroll, P.R. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int., 2012, 110(1), 50-55.
31. Ruutu, M.; Rannikko, A. Words of wisdom. Re: Active surveillance for the management of prostate cancer in a contemporary cohort. Dall’Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Cancer 2008;112: 2664-70. Eur. Urol., 2009, 55(1), 244-245.
32. Mullerad, M.; Hricak, H.; Kuroiwa, K.; Pucar, D.; Chen, H.N.; Kattan, M.W.; Scardino, P.T. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J. Urol., 2005, 174(6), 2158-2163.
33. Kattan, M.W.; Eastham, J.A.; Stapleton, A.M.; Wheeler, T.M.; Scardino, P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst., 1998, 90(10), 766-771.
34. D’Amico, A.V.; Whittington, R.; Malkowicz, S.B.; Cote, K.; Loffredo, M.; Schultz, D.; Chen, M.H.; Tomaszewski, J.E.; Renshaw, A.A.; Wein, A.; Richie, J.P. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer, 2002, 95(2), 281-286.
35. Megwalu, II; Ferguson, G.G.; Wei, J.T.; Mouraviev, V.; Polascik, T.J.; Taneja, S.; Black, L.; Andriole, G.L.; Kibel, A.S. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int., 2008, 102(5), 546-550.
36. Cowherd, S.M. Tumor staging and grading: a primer. Methods Mol. Biol., 2012, 823, 1-18.
37. Gleason, D.F. Classification of prostatic carcinomas. Cancer Chemother. Rep., 1966, 50(3), 125-128.
38. Orozco, R.; O’Dowd, G.; Kunnel, B.; Miller, M.C.; Veltri, R.W. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology, 1998, 51(2), 186-195.
39. O’Dowd, G.J.; Veltri, R.W.; Orozco, R.; Miller, M.C.; Oesterling, J.E. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J. Urol., 1997, 158(3 Pt 1), 687-698.
40. Epstein, J.I.; Lecksell, K.; Carter, H.B. Prostate cancer sampled on sextant needle biopsy: significance of cancer on multiple cores from different areas of the prostate. Urology, 1999, 54(2), 291-294.
41. O’Dowd G, J.; Miller, M.C.; Orozco, R.; Veltri, R.W. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology, 2000, 55(4), 553-559.
42. Sakr, W.A.; Tefilli, M.V.; Grignon, D.J.; Banerjee, M.; Dey, J.; Gheiler, E.L.; Tiguert, R.; Powell, I.J.; Wood, D.P. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology, 2000, 56(5), 730-734.
43. Chan, T.Y.; Partin, A.W.; Walsh, P.C.; Epstein, J.I. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology, 2000, 56(5), 823-827.
44. Flanigan, R.C.; Catalona, W.J.; Richie, J.P.; Ahmann, F.R.; Hudson, M.A.; Scardino, P.T.; deKernion, J.B.; Ratliff, T.L.; Kavoussi, L.R.; Dalkin, B.L.; et al. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J. Urol., 1994, 152(5 Pt 1), 1506-1509.
45. Carter, H.B.; Hamper, U.M.; Sheth, S.; Sanders, R.C.; Epstein, J.I.; Walsh, P.C. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J. Urol., 1989, 142(4), 1008-1010.
46. Jadvar, H. Molecular imaging of prostate cancer with PET. J. Nucl. Med., 2013, 54(10), 1685-1688.
47. Hara, T.; Kosaka, N.; Kishi, H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med., 1998, 39(6), 990-995.
48. Oyama, N.; Kim, J.; Jones, L.A.; Mercer, N.M.; Engelbach, J.A.; Sharp, T.L.; Welch, M.J. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nucl. Med. Biol., 2002, 29(8), 783-790.
49. Rietbergen, D.D.; van der Hiel, B.; Vogel, W.; Stokkel, M.P. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT. Nucl. Med. Commun., 2011, 32(12), 1143-1147.
50. DeGrado, T.R.; Reiman, R.E.; Price, D.T.; Wang, S.; Coleman, R.E. Pharmacokinetics and radiation dosimetry of 18Ffluorocholine. J. Nucl. Med., 2002, 43(1), 92-96.
51. Brogsitter, C.; Zophel, K.; Kotzerke, J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(Suppl 1), S18-27.
52. Watanabe, H.; Kanematsu, M.; Kondo, H.; Kako, N.; Yamamoto, N.; Yamada, T.; Goshima, S.; Hoshi, H.; Bae, K.T. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging. J. Magn. Reson. Imaging, 2010, 31(5), 1151-1156.
53. Mariani, G.; Bruselli, L.; Kuwert, T.; Kim, E.E.; Flotats, A.; Israel, O.; Dondi, M.; Watanabe, N. A review on the clinical uses of SPECT/CT. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(10), 1959-1985.
54. Romer, W.; Olk, A.; Hennig, F.F.; Bautz, W.; Kuwert, T. Assessment of aseptic loosening of the acetabular component in a total hip replacement with 99mTc-DPD-SPECT/spiral-CT hybrid imaging. Nuklearmedizin, 2005, 44(6), N58-60.
55. Turkbey, B.; Mena, E.; Aras, O.; Garvey, B.; Grant, K.; Choyke, P.L. Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer. Clin. Oncol. (R Coll Radiol), 2013, 25(8), 451-460.
56. Kim, C.K.; Park, B.K.; Kim, B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrastenhanced imaging. J. Comput. Assist. Tomogr., 2006, 30(1), 7-11.
57. Nakashima, J.; Tanimoto, A.; Imai, Y.; Mukai, M.; Horiguchi, Y.; Nakagawa, K.; Oya, M.; Ohigashi, T.; Marumo, K.; Murai, M. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology, 2004, 64(1), 101-105.
58. Turkbey, B.; Mani, H.; Aras, O.; Rastinehad, A.R.; Shah, V.; Bernardo, M.; Pohida, T.; Daar, D.; Benjamin, C.; McKinney, Y.L.; Linehan, W.M.; Wood, B.J.; Merino, M.J.; Choyke, P.L.; Pinto, P.A. Correlation of magnetic resonance imaging tumor volume with histopathology. J. Urol., 2012, 188(4), 1157-1163.
59. Panebianco, V.; Sciarra, A.; Marcantonio, A.; Forte, V.; Biondi, T.; Laghi, A.; Catalano, C. Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer. Q J. Nucl. Med. Mol. Imaging, 2012, 56(4), 331-342.
60. Tan, C.H.; Wei, W.; Johnson, V.; Kundra, V. Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR Am. J. Roentgenol., 2012, 199(4), 822-829.
61. Wu, L.M.; Xu, J.R.; Gu, H.Y.; Hua, J.; Chen, J.; Zhang, W.; Zhu, J.; Ye, Y.Q.; Hu, J. Usefulness of diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer. Acad. Radiol., 2012, 19(10), 1215-1224.
62. Iraha, Y.; Murayama, S.; Kamiya, A.; Iraha, S.; Ogawa, K. Diffusion-weighted MRI and PSA correlations in patients with prostate cancer treated with radiation and hormonal therapy. Anticancer Res., 2012, 32(10), 4467-4471.
63. Rinaldi, D.; Fiocchi, F.; Ligabue, G.; Bianchi, G.; Torricelli, P. Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation. Radiol. Med., 2012, 117(8), 1429-1440.
64. Ocak, I.; Bernardo, M.; Metzger, G.; Barrett, T.; Pinto, P.; Albert, P.S.; Choyke, P.L. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am. J. Roentgenol., 2007, 189(4), 849.
65. Nicholson, B.; Schaefer, G.; Theodorescu, D. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev., 2001, 20(3-4), 297-319.
66. Concato, J.; Jain, D.; Li, W.W.; Risch, H.A.; Uchio, E.M.; Wells, C.K. Molecular markers and mortality in prostate cancer. BJU Int., 2007, 100(6), 1259-1263.
67. Noworolski, S.M.; Vigneron, D.B.; Chen, A.P.; Kurhanewicz, J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn. Reson. Imaging, 2008, 26(8), 1071-1080.
68. Pinto, F.; Totaro, A.; Palermo, G.; Calarco, A.; Sacco, E.; D’Addessi, A.; Racioppi, M.; Valentini, A.; Gui, B.; Bassi, P. Imaging in prostate cancer staging: present role and future perspectives. Urol. Int., 2012, 88(2), 125-136.
69. Bloch, B.N.; Furman-Haran, E.; Helbich, T.H.; Lenkinski, R.E.; Degani, H.; Kratzik, C.; Susani, M.; Haitel, A.; Jaromi, S.; Ngo, L.; Rofsky, N.M. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology, 2007, 245(1), 176-185.
70. Jung, J.A.; Coakley, F.V.; Vigneron, D.B.; Swanson, M.G.; Qayyum, A.; Weinberg, V.; Jones, K.D.; Carroll, P.R.; Kurhanewicz, J. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology, 2004, 233(3), 701-708.
71. Chen, X.; Park, R.; Hou, Y.; Tohme, M.; Shahinian, A.H.; Bading, J.R.; Conti, P.S. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med., 2004, 45(8), 1390-1397.
72. Patel, O.; Shulkes, A.; Baldwin, G.S. Gastrin-releasing peptide and cancer. Biochim Biophys Acta, 2006, 1766(1), 23-41.
73. Prasanphanich, A.F.; Nanda, P.K.; Rold, T.L.; Ma, L.; Lewis, M.R.; Garrison, J.C.; Hoffman, T.J.; Sieckman, G.L.; Figueroa, S.D.; Smith, C.J. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrinreleasing peptide receptor-expressing tissues. Proc. Natl. Acad. Sci. U. S. A., 2007, 104(30), 12462-12467.
74. Chanda, N.; Kattumuri, V.; Shukla, R.; Zambre, A.; Katti, K.; Upendran, A.; Kulkarni, R.R.; Kan, P.; Fent, G.M.; Casteel, S.W.; Smith, C.J.; Boote, E.; Robertson, J.D.; Cutler, C.; Lever, J.R.; Katti, K.V.; Kannan, R. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(19), 8760-8765.
75. Wei, L.; Li, S.; Yang, J.; Ye, Y.; Zou, J.; Wang, L.; Long, R.; Zurkiya, O.; Zhao, T.; Johnson, J.; Qiao, J.; Zhou, W.; Castiblanco, A.; Maor, N.; Chen, Y.; Mao, H.; Hu, X.; Yang, J.J.; Liu, Z.R. Protein-based MRI contrast agents for molecular imaging of prostate cancer. Mol. Imaging Biol., 2011, 13(3), 416-423.
76. Qiao, J.; Li, S.; Wei, L.; Jiang, J.; Long, R.; Mao, H.; Wang, L.; Yang, H.; Grossniklaus, H.E.; Liu, Z.R.; Yang, J.J. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One, 2011, 6(3), e18103.
77. Yu, W.W.; Chang, E.; Drezek, R.; Colvin, V.L. Water-soluble quantum dots for biomedical applications. Biochem. Biophys. Res. Commun., 2006, 348(3), 781-786.
78. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 2005, 307(5709), 538-544.
79. Pinaud, F.; Michalet, X.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Iyer, G.; Weiss, S. Advances in fluorescence imaging with quantum dot bio-probes. Biomaterials, 2006, 27(9), 1679-1687.
80. Sardana, G.; Dowell, B.; Diamandis, E.P. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem., 2008, 54(12), 1951-1960.
81. Shin, C.; Mok, K.H.; Han, J.H.; Ahn, J.H.; Lim, Y. Conformational analysis in solution of gastrin releasing peptide. Biochem. Biophys. Res. Commun., 2006, 350(1), 120-124.
82. Anastasi, A.; Erspamer, V.; Bucci, M. Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia, 1971, 27(2), 166-167.
83. Jensen, R.T.; Battey, J.F.; Spindel, E.R.; Benya, R.V. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev., 2008, 60(1), 1-42.
84. Schroeder, R.P.; van Weerden, W.M.; Bangma, C.; Krenning, E.P.; de Jong, M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods, 2009, 48(2), 200-204.
85. Davis, M.I.; Bennett, M.J.; Thomas, L.M.; Bjorkman, P.J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(17), 5981-5986.
86. Wynant, G.E.; Murphy, G.P.; Horoszewicz, J.S.; Neal, C.E.; Collier, B.D.; Mitchell, E.; Purnell, G.; Tyson, I.; Heal, A.; Abdel-Nabi, H.; et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate, 1991, 18(3), 229-241.
87. Troyer, J.K.; Beckett, M.L.; Wright, G.L.; Jr. Location of prostatespecific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate, 1997, 30(4), 232-242.
88. Osborne, J.R.; Akhtar, N.H.; Vallabhajosula, S.; Anand, A.; Deh, K.; Tagawa, S.T. Prostate-specific membrane antigen-based imaging. Urol. Oncol., 2013, 31(2), 144-154.
89. Qiao, J.; Li, S.; Wei, L.; Jiang, J.; Long, R.; Mao, H.; Wei, L.; Wang, L.; Yang, H.; Grossniklaus, H.E.; Liu, Z.R.; Yang, J.J. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One, 2011, 6(3), e18103.
90. Banerjee, S.R.; Pullambhatla, M.; Foss, C.A.; Nimmagadda, S.; Ferdani, R.; Anderson, C.J.; Mease, R.C.; Pomper, M.G. (6)(4)Culabeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. J. Med. Chem., 2014, 57(6), 2657-2669.
91. Hillier, S.M.; Maresca, K.P.; Femia, F.J.; Marquis, J.C.; Foss, C.A.; Nguyen, N.; Zimmerman, C.N.; Barrett, J.A.; Eckelman, W.C.; Pomper, M.G.; Joyal, J.L.; Babich, J.W. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res., 2009, 69(17), 6932-6940.
92. Wang, L.; Li, L.; Guo, Y.; Tong, H.; Fan, X.; Ding, J.; Huang, H. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer. Prostate, 2013, 73(11), 1147-1158.
93. Schol, D.; Fleron, M.; Greisch, J.F.; Jaeger, M.; Frenz, M.; De Pauw, E.; De Pauw-Gillet, M.C. Anti-PSMA antibody-coupled gold nanorods detection by optical and electron microscopies. Micron, 2013, 50, 68-74.
94. Gonzalez, L.C. Protein microarrays, biosensors, and cell-based methods for secretome-wide extracellular protein-protein interaction mapping. Methods, 2012, 57(4), 448-458.
95. Sugimoto, Y.; Hirota, M.; Yoshikawa, K.; Sumitomo, M.; Nakamura, K.; Ueda, R.; Niwa, R.; Suzawa, T.; Yamasaki, M.; Shitara, K.; Kato, T.; Nakamura, K. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer. Anticancer Res., 2014, 34(1), 89-97.
96. Banerjee, S.R.; Pullambhatla, M.; Shallal, H.; Lisok, A.; Mease, R.C.; Pomper, M.G. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget, 2011, 2(12), 1244-1253.
97. Shen, D.; Xie, F.; Edwards, W.B. Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA). PLoS One, 2013, 8(7), e68339.
98. Caravan, P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem. Soc. Rev., 2006, 35(6), 512-523.
99. De Leon-Rodriguez, L.M.; Lubag, A.J.; Malloy, C.R.; Martinez, G.V.; Gillies, R.J.; Sherry, A.D. Responsive MRI agents for sensing metabolism in vivo. Acc. Chem. Res., 2009, 42(7), 948-957.
100. Major, J.L.; Meade, T.J. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc. Chem. Res., 2009, 42(7), 893-903.
101. Xue, S.; Qiao, J.; Jiang, J.; Hubbard, K.; White, N.; Wei, L.; Li, S.; Liu, Z.R.; Yang, J.J. Design of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers. Med. Res. Rev., 2014, 34(5), 1070-1099.
102. Tóth, É.; Helm, L.; Merbach, A. Relaxivity of MRI Contrast Agents, in Contrast Agents I, W. Krause, Editor. 2002, Springer Berlin Heidelberg. p. 61-101.
103. Solomon, I. Relaxation Processes in a System of Two Spins. Phys. Rev., 1955, 99(2), 559-565.
104. Bloembergen, N. Proton relaxation times in paramagnetic solutions. J. Chem. Phys., 1957, 27(2), 572-573.
105. Karfeld-Sulzer, L.S.; Waters, E.A.; Davis, N.E.; Meade, T.J.; Barron, A.E. Multivalent protein polymer MRI contrast agents: controlling relaxivity via modulation of amino acid sequence. Biomacromolecules, 2010, 11(6), 1429-1436.
106. Fulton, D.A.; O’Halloran, M.; Parker, D.; Senanayake, K.; Botta, M.; Aime, S. Efficient relaxivity enhancement in dendritic gadolinium complexes: effective motional coupling in medium molecular weight conjugates. Chem. Commun. (Camb), 2005, (4), 474-476.
107. Aime, S.; Gianolio, E.; Terreno, E.; Giovenzana, G.B.; Pagliarin, R.; Sisti, M.; Palmisano, G.; Botta, M.; Lowe, M.P.; Parker, D. Ternary Gd(III)L-HSA adducts: evidence for the replacement of inner-sphere water molecules by coordinating groups of the protein. Implications for the design of contrast agents for MRI. J. Biol. Inorg. Chem., 2000, 5(4), 488-497.
108. Aime, S.; D’Amelio, N.; Fragai, M.; Lee, Y.M.; Luchinat, C.; Terreno, E.; Valensin, G. A paramagnetic probe to localize residues next to carboxylates on protein surfaces. J. Biol. Inorg. Chem., 2002, 7(6), 617-622.
109. Qiao, J.; Xue, S.; Pu, F.; White, N.; Jiang, J.; Liu, Z.R.; Yang, J.J. Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J. Biol. Inorg. Chem., 2014, 19(2), 259-270.
110. De Jong, W.H.; Hagens, W.I.; Krystek, P.; Burger, M.C.; Sips, A.J.; Geertsma, R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials, 2008, 29(12), 1912-1919.
111. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev., 2011, 63(3), 136-151.
112. Xue, S.; Qiao, J.; Pu, F.; Cameron, M.; Yang, J.J. Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2013, 5(2), 163-179.
113. Li, S.; Jiang, J.; Zou, J.; Qiao, J.; Xue, S.; Wei, L.; Long, R.; Wang, L.; Castiblanco, A.; White, N.; Ngo, J.; Mao, H.; Liu, Z.R.; Yang, J.J. PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities. J. Inorg. Biochem., 2012, 107(1), 111-118.
114. Yang, J.J.; Yang, J.; Wei, L.; Zurkiya, O.; Yang, W.; Li, S.; Zou, J.; Zhou, Y.; Maniccia, A.L.; Mao, H.; Zhao, F.; Malchow, R.; Zhao, S.; Johnson, J.; Hu, X.; Krogstad, E.; Liu, Z.R. Rational design of protein-based MRI contrast agents. J. Am. Chem. Soc., 2008, 130(29), 9260-9267.
115. Pidcock, E.; Moore, G.R. Structural characteristics of protein binding sites for calcium and lanthanide ions. J. Biol. Inorg. Chem., 2001, 6(5-6), 479-489.
116. Ye, Y.; Lee, H.W.; Yang, W.; Shealy, S.; Yang, J.J. Probing sitespecific calmodulin calcium and lanthanide affinity by grafting. J. Am. Chem. Soc., 2005, 127(11), 3743-3750.
117. Ye, Y.; Shealy, S.; Lee, H.W.; Torshin, I.; Harrison, R.; Yang, J.J. A grafting approach to obtain site-specific metal-binding properties of EF-hand proteins. Protein Eng., 2003, 16(6), 429-434.
118. Zhou, Y.; Frey, T.K.; Yang, J.J. Viral calciomics: interplays between Ca2+ and virus. Cell Calcium, 2009, 46(1), 1-17.
119. Huang, Y.; Zhou, Y.; Wong, H.C.; Castiblanco, A.; Chen, Y.; Brown, E.M.; Yang, J.J. Calmodulin regulates Ca2+-sensing receptor-mediated Ca2+ signaling and its cell surface expression. J. Biol. Chem., 2010, 285(46), 35919-35931.
120. Jiang, Y.; Huang, Y.; Wong, H.C.; Zhou, Y.; Wang, X.; Yang, J.; Hall, R.A.; Brown, E.M.; Yang, J.J. Elucidation of a novel extracellular calcium-binding site on metabotropic glutamate receptor 1{alpha} (mGluR1{alpha}) that controls receptor activation. J. Biol. Chem., 2010, 285(43), 33463-33474.
121. Chen, Y.; Xue, S.; Zou, J.; Lopez, J.R.; Yang, J.J.; Perez, C.F. Myoplasmic resting Ca2+ regulation by ryanodine receptors is under the control of a novel Ca2+-binding region of the receptor. Biochem. J., 2014, 460(2), 261-271.
122. Zhou, Y.; Xue, S.; Chen, Y.; Yang, J.J. Probing Ca2+-binding capability of viral proteins with the EF-hand motif by grafting approach. Methods Mol. Biol., 2013, 963, 37-53.
123. Zhou, Y.; Xue, S.; Yang, J.J. Calciomics: integrative studies of Ca2+-binding proteins and their interactomes in biological systems. Metallomics, 2013, 5(1), 29-42.
124. Yanyi, C.; Shenghui, X.; Yubin, Z.; Jie, Y.J. Calciomics: prediction and analysis of EF-hand calcium binding proteins by protein engineering. Sci. China Chem., 2010, 53(1), 52-60.
125. Chen, Y.; Naik, S.G.; Krzystek, J.; Shin, S.; Nelson, W.H.; Xue, S.; Yang, J.J.; Davidson, V.L.; Liu, A. Role of calcium in metalloenzymes: effects of calcium removal on the axial ligation geometry and magnetic properties of the catalytic diheme center in MauG. Biochemistry, 2012, 51(8), 1586-1597.
126. Yoshimura, T.; Fujita, K.; Kawakami, S.; Takeda, K.; Chan, S.; Beligere, G.; Dowell, B. Stability of pro-gastrin-releasing peptide in serum versus plasma. Tumour Biol., 2008, 29(4), 224-230.
127. Stura, E.A.; Muller, B.H.; Bossus, M.; Michel, S.; Jolivet-Reynaud, C.; Ducancel, F. Crystal structure of human prostate-specific antigen in a sandwich antibody complex. J. Mol. Biol., 2011, 414(4), 530-544.
128. Young, S.H.; Rozengurt, E. Qdot nanocrystal conjugates conjugated to bombesin or ANG II label the cognate G proteincoupled receptor in living cells. Am. J. Physiol. Cell Physiol., 2006, 290(3), C728-732.
129. Chen, H.; Wan, S.; Zhu, F.; Wang, C.; Cui, S.; Du, C.; Ma, Y.; Gu, Y. A fast tumor-targeting near-infrared fluorescent probe based on bombesin analog for in vivo tumor imaging. Contrast Media Mol. Imaging, 2014, 9(2), 122-134.
130. Cai, Q.Y.; Yu, P.; Besch-Williford, C.; Smith, C.J.; Sieckman, G.L.; Hoffman, T.J.; Ma, L. Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases. Prostate, 2013, 73(8), 842-854.
131. Pan, D.; Yan, Y.; Yang, R.; Xu, Y.P.; Chen, F.; Wang, L.; Luo, S.; Yang, M. PET imaging of prostate tumors with (18) F-Al-NOTAMATBBN. Contrast Media Mol. Imaging, 2014, 9(5), 342-348.
132. Varasteh, Z.; Aberg, O.; Velikyan, I.; Lindeberg, G.; Sorensen, J.; Larhed, M.; Antoni, G.; Sandstrom, M.; Tolmachev, V.; Orlova, A. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPRtargeted tumor imaging. PLoS One, 2013, 8(12), e81932.
133. Liu, Y.; Hu, X.; Liu, H.; Bu, L.; Ma, X.; Cheng, K.; Li, J.; Tian, M.; Zhang, H.; Cheng, Z. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. J. Nucl. Med., 2013, 54(12), 2132-2138.
134. Asti, M.; Iori, M.; Capponi, P.C.; Atti, G.; Rubagotti, S.; Martin, R.; Brennauer, A.; Muller, M.; Bergmann, R.; Erba, P.A.; Versari, A. Influence of different chelators on the radiochemical properties of a 68-Gallium labelled bombesin analogue. Nucl. Med. Biol., 2014, 41(1), 24-35.
135. Varasteh, Z.; Rosenstrom, U.; Velikyan, I.; Mitran, B.; Altai, M.; Honarvar, H.; Rosestedt, M.; Lindeberg, G.; Sorensen, J.; Larhed, M.; Tolmachev, V.; Orlova, A. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin. Molecules, 2014, 19(7), 10455-10472.
136. Kahkonen, E.; Jambor, I.; Kemppainen, J.; Lehtio, K.; Gronroos, T.J.; Kuisma, A.; Luoto, P.; Sipila, H.J.; Tolvanen, T.; Alanen, K.; Silen, J.; Kallajoki, M.; Roivainen, A.; Schafer, N.; Schibli, R.; Dragic, M.; Johayem, A.; Valencia, R.; Borkowski, S.; Minn, H. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin. Cancer Res., 2013, 19(19), 5434-5443.
137. Jimenez-Mancilla, N.; Ferro-Flores, G.; Santos-Cuevas, C.; Ocampo-Garcia, B.; Luna-Gutierrez, M.; Azorin-Vega, E.; Isaac-Olive, K.; Camacho-Lopez, M.; Torres-Garcia, E. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3)-bombesin internalized in nuclei of prostate cancer cells. J. Labelled Comp. Radiopharm., 2013, 56(13), 663-671.
138. Mather, S.J.; Nock, B.A.; Maina, T.; Gibson, V.; Ellison, D.; Murray, I.; Sobnack, R.; Colebrook, S.; Wan, S.; Halberrt, G.; Szysko, T.; Powles, T.; Avril, N. GRP Receptor Imaging of Prostate Cancer Using [(99m)Tc]Demobesin 4: a First-in-Man Study. Mol. Imaging Biol., 2014, 16(6), 888-895.
139. Zhou, Z.; Wagh, N.K.; Ogbomo, S.M.; Shi, W.; Jia, Y.; Brusnahan, S.K.; Garrison, J.C. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J. Nucl. Med., 2013, 54(9), 1605-1612.
140. Chang, Y.J.; Yu, C.Y.; Hsu, C.W.; Lee, W.C.; Chen, S.J.; Chang, C.H.; Lee, T.W. Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumor-bearing mice. Oncol. Rep., 2012, 28(5), 1736-1742.
141. Dapp, S.; Muller, C.; Garayoa, E.G.; Blauenstein, P.; Maes, V.; Brans, L.; Tourwe, D.A.; Schibli, R. PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues. EJNMMI Res., 2012, 2(1), 24.
142. Wang, X.L.; Xu, R.; Wu, X.; Gillespie, D.; Jensen, R.; Lu, Z.R. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol. Pharm., 2009, 6(3), 738-746.
143. Sioud, M.; Mobergslien, A. Efficient siRNA targeted delivery into cancer cells by gastrin-releasing peptides. Bioconjug. Chem., 2012, 23(5), 1040-1049.
144. Horoszewicz, J.S.; Kawinski, E.; Murphy, G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res., 1987, 7(5B), 927-935.
145. Troyer, J.K.; Feng, Q.; Beckett, M.L.; Wright, G.L.; Jr. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol., 1995, 1(1), 29-37.
146. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 1997, 57(17), 3629-3634.
147. Michaels, E.K.; Blend, M.; Quintana, J.C. 111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J. Urol., 1999, 161(2), 597-598.
148. Bander, N.H.; Milowsky, M.I.; Nanus, D.M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S.J. Phase I trial of 177lutetiumlabeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol., 2005, 23(21), 4591-4601.
149. Holland, J.P.; Divilov, V.; Bander, N.H.; Smith-Jones, P.M.; Larson, S.M.; Lewis, J.S. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med., 2010, 51(8), 1293-1300.
150. Gao, X.; Cui, Y.; Levenson, R.M.; Chung, L.W.; Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 2004, 22(8), 969-976.
151. Alt, K.; Wiehr, S.; Ehrlichmann, W.; Reischl, G.; Wolf, P.; Pichler, B.J.; Elsasser-Beile, U.; Buhler, P. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Culabeled antibodies against native cell-adherent PSMA. Prostate, 2010, 70(13), 1413-1421.
152. Grauer, L.S.; Lawler, K.D.; Marignac, J.L.; Kumar, A.; Goel, A.S.; Wolfert, R.L. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM’ protein in the LNCaP prostatic carcinoma cell line. Cancer Res., 1998, 58(21), 4787-4789.
153. Murphy, G.P.; Greene, T.G.; Tino, W.T.; Boynton, A.L.; Holmes, E.H. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol., 1998, 160(6 Pt 2), 2396-2401.
154. Chen, Y.; Pullambhatla, M.; Banerjee, S.R.; Byun, Y.; Stathis, M.; Rojas, C.; Slusher, B.S.; Mease, R.C.; Pomper, M.G. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug. Chem., 2012, 23(12), 2377-2385.
155. Kim, D.; Jeong, Y.Y.; Jon, S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano, 2010, 4(7), 3689-3696.
156. Tse, B.W.; Cowin, G.J.; Soekmadji, C.; Jovanovic, L.; Vasireddy, R.S.; Ling, M.T.; Khatri, A.; Liu, T.; Thierry, B.; Russell, P.J. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine (Lond), 2014, 2014, 1-12.
157. Abdolahi, M.; Shahbazi-Gahrouei, D.; Laurent, S.; Sermeus, C.; Firozian, F.; Allen, B.J.; Boutry, S.; Muller, R.N. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAbconjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol. Imaging, 2013, 8(2), 175-184.
158. Ruggiero, A.; Holland, J.P.; Hudolin, T.; Shenker, L.; Koulova, A.; Bander, N.H.; Lewis, J.S.; Grimm, J. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J. Nucl. Med., 2011, 52(10), 1608-1615.
159. Foss, C.A.; Mease, R.C.; Fan, H.; Wang, Y.; Ravert, H.T.; Dannals, R.F.; Olszewski, R.T.; Heston, W.D.; Kozikowski, A.P.; Pomper, M.G. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res., 2005, 11(11), 4022-4028.
160. Zechmann, C.M.; Afshar-Oromieh, A.; Armor, T.; Stubbs, J.B.; Mier, W.; Hadaschik, B.; Joyal, J.; Kopka, K.; Debus, J.; Babich, J.W.; Haberkorn, U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(7), 1280-1292.
161. Lesche, R.; Kettschau, G.; Gromov, A.V.; Bohnke, N.; Borkowski, S.; Monning, U.; Hegele-Hartung, C.; Dohr, O.; Dinkelborg, L.M.; Graham, K. Preclinical evaluation of BAY 1075553, a novel (18)Flabelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(1), 89-101.
162. Afshar-Oromieh, A.; Haberkorn, U.; Schlemmer, H.P.; Fenchel, M.; Eder, M.; Eisenhut, M.; Hadaschik, B.A.; Kopp-Schneider, A.; Rothke, M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(5), 887-897.
163. Kampmeier, F.; Williams, J.D.; Maher, J.; Mullen, G.E.; Blower, P.J. Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Res., 2014, 4(1), 13.
164. Hillier, S.M.; Maresca, K.P.; Lu, G.; Merkin, R.D.; Marquis, J.C.; Zimmerman, C.N.; Eckelman, W.C.; Joyal, J.L.; Babich, J.W. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J. Nucl. Med., 2013, 54(8), 1369-1376.
165. DiPippo, V.A.; Olson, W.C.; Nguyen, H.M.; Brown, L.G.; Vessella, R.L.; Corey, E. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate, 2015, 75(3), 303-313.
166. Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(45), 17356-17361.